year 11, Issue 1 (March - April 2017)                   Iran J Med Microbiol 2017, 11(1): 75-82 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Masoumifard S, Khezri P, Mohammadzadeh haji pirlo H, Heshmatiayan B, Khademvatan S, Manafpour N. The effect of the Persian Gulf brown algae extract (Sargassum Oligocystum) on Leishmania major (MRHO/IR/75/ER) in vitro. Iran J Med Microbiol. 2017; 11 (1) :75-82
1- Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran
2- Cellular and Molecular Research Center & Department of Parasitology and Mycology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
3- Department of Physiology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
4- Cellular and Molecular Research Center & Department of Parasitology and Mycology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran ,
5- Montgomery College, Maryland, USA, 20850
Abstract:   (6298 Views)

Background and Aim: Leishmaniasis is a disease which caused by Leishmania protozoan parasitic. Plant extracts and their derived compounds, provide a rich source of medicinal compounds which is by the World Health Organization considered as a candidate drug for the treatment of many diseases. This study aimed to evaluate anti-Leishmania effects of Persian Gulf brown algae extract compared to meglumine control drug in vitro.

Materials and Methods: Leishmania major promastigotes were cultured in RPMI-1640 medium containing 10% FBS and antibiotics, at temperature 1 ± 24 and the effect of different concentrations of Persian Gulf brown algae was evaluated by MTT assay in comparison with meglumine on Leishmania major promastigotes. The optical density was read by ELISA reader at wavelength of 540-630 nm. The results are expressed as IC50 (Inhibitory Concentration %50).

Results: The IC50 amount of extract obtained as 20 μg/ mL for Leishmania major after 72 hours of incubation. So that the IC50 amount of meglumine control drug is 21.8 μg/mL for Leishmania major.

Conclusions: The effectiveness of these extracts on these parasites is roughly equivalent meglumine and have the potential of using as an anti-Leishmania drug but there is need to do more tests to assess effects of this extract on Leishmania agents in animal models and In vivo. 

Full-Text [PDF 843 kb]   (1583 Downloads)    
Type of Study: Original | Subject: Medical Parasitology
Received: 2017/01/22 | Accepted: 2017/04/4 | ePublished: 2017/04/24

1. Davies CR, Mazloumi Gavgani AS. Ageacquired immunity and the risk of visceralleishmaniasis: a prospective study in Iran.Parasitology 1999; 119(3): 247-257. [PubMed]
2. Saki J, Meamar AR, Oormazdi H, Akhlaghi L,Maraghi S, Mohebali M, et al. Mini-Exon genotyping of leishmania species in Khouzestan province, southwest of Iran. Iran J Parasitol 2010; 5(1): 25-34. [Article]
3. Desjeux P. Leishmaniasis. current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004;27:305–318 [PubMed]
4. Katakura K. Molecular epidemiology of leishmaniasis in Asia (focus on cutaneous infections). Curr Opin Infect Dis 2009; 22(2):126-30. [PubMed]
5. Costa LE,Goulart LR, Pereira NC, Lima MI, Duarte MC, et al. Mimotope–Based Vaccines of Leishmania infantum Antigens and their Protective Efficacy against Visceral Leishmaniasis. Pols One. 2014; 9(10):1-13. [PubMed]
6. Nadeem A, Javadian E, seiedi-Rashti A. Epidemiology Leishmaniasis in Iran:in Leishmania and Leishmaniasis. Tehran:Tehran university publication center;1994.p176-200.
7. Ahmadi K, Mahmoudzadeh PA, Esfahani AA. Effect of garlic extract on cutaneous leishmaniasis and the role of nitric oxide. Iran J Med Sci 2002; 27: 97-100. [Article]
8. Croft SL, Seifert K, Yardley V. Current scenario of drug development for leishmaniasis. Indian J Med Res 2006;123(3):399-410. [PubMed]
9. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Travel Med Infect Dis 2007;5(3):150-8 [PubMed]
10. Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharm Des 2002;8(4):319-42. [PubMed]
11. Mishra BB, Kale RR, Singh RK, Tiwari VK. Alkaloids: Future prospective to combat leishmaniasis. Fitoterapia 2009; 80(2): 81. [PubMed]
12. Kolodziej H, Kiderlen AF. Antileishmanial activity and immune modulatory effects of tannins and related compounds on Leishmania parasitised RAW 264.7 cells. Phytochemistry 2005;66(17):2056-71. [PubMed]
13. Lamidi M, DiGiorgio C, Delmas F, Favel A, Eyele Mve-Mba C, Rondi ML, et al. In vitro cytotoxic, antileishmanial and antifungal activities of ethnopharmacologically selected Gabonese plants. J Ethnopharmacol 2005;102(2):185-90. [Article]
14. Rates S M. plant as source of drugs.Toxicon 2007; 39(5):603-13. [PubMed]
15. Abbasi N, Azizi F, Abdi M, Saifmanesh M. A Comparative Study of the Antimicrobial Effect of Scrophularia striata Boiss. Extract and Selective Antibiotics Against Staphylococcus aureus and Pesudomonas aeroginosa. J Med Plants 2007; 1(Sup3):10-18. [Article]
16. Kotnala S, Garg A, Chatterji A. Screening for the presence of antimicrobial activity in Few Indian seaweeds. Pertanika J Trop Agric Sci 2009; 32(1):69-75. [Article]
17. Taskin E, Ozturk M, Kurt O. Antibacterial activities of some marine algae from the Aegean Sea (Turkey). African J Biotechnol 2007;6(24):2746-51. [Article]
18. Barsanti L, Gualtieri P. Algae anatomy, biochemistry and biotechnology. New York: Taylor and Francis Group; 2006. [Article]
19. Yeh ST, Lee CS, Chen J C. Administrasion of hot water extract of brown seaweed Sargassum duplicatum via immersion and injection enhances the immune resistance of white shrimp Litopenaeus vannamei. Fish Shellfish Immunol 2006; 20: 332-345. [PubMed]
20. Zhuang C, Itoh H, Mizuno T. Ito H. Antitumor active fucoidan from the brown seaweed Umitoranoo (Sargassum thunbergii). Biosci Biotechnol Bi 1995;59: 563– 567. [PubMed]
21. Feily A, Saki J, Maraghi S, Moosavi Z, Khademvatan S, Siahpoosh A. In vitro activity of green tea extract against Leishmania major promastigotes. Int J Clin Pharmacol Ther 2012; 50(3):233–6. [PubMed]
22. Khademvatan S, Adibpour N, Eskandari A, Rezaee S, Hashemitabar M, Rahim F. In silico and in vitro comparative activity of novel experimental derivatives against Leishmania major and Leishmania infantum promastigotes. Exp Parasitol 2013; 135(2):208–16. [PubMed]
23. Khademvatan S, Gharavi MJ, Akhlaghi L, Samadikuchaksaraei A, Mousavizadeh K, Hadighi R, Saki J. Induction of apoptosis by miltefosine in Iranian strain of Leishmania infantum promastigotes. Iran J Parasitol 2009; 4 (2): 23-31. [Article]
24. Poorrajab F, Ardestani SK, Foroumadi A, Emami S, Kariminia A, Behrouzi- Fardmoghadam M. et al. Selective leishmanicidal effect of 1,3,4-thiadiazole derivatives and possible mechanism of action against Leishmania species. Exp Parasitol 2009; 121, 323-30. [PubMed]
25. Khademvatan S, Saki J, Gharavi MJ, Rahim F. Allium sativum extract induces apoptosis in leishmania major (MRHO/IR/75/ER) promastigotes, J Med plants Res 2011; 16:3725-32. [Article]
26. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19, 111-26. [PubMed]
27. Stella Mary J, Vinotha P, Andrew M. Pradeep. Screening for in vitro Cytotoxic Activity of Seaweed, Sargassum sp. Against Hep-2 and MCF-7 Cancer Cell Line. Asian Pacific J Cancer Prev2012; 13(12):6073-6076. [PubMed]
28. Zandi K, Ahmadzadeh S, Tajbakhsh S, rTastian Z, Yousefi F, Farshadpour F, Sartavi K. Anticancer activity of Sargassum oligocystum water extract against human cancer cell lines. Eur Rev Med. Pharmacol Sci 2010; 14: 669-673. [PubMed]

Add your comments about this article : Your username or Email:

Send email to the article author

© 2020 All Rights Reserved | Iranian Journal of Medical Microbiology

Designed & Developed by : Yektaweb | Publisher: Farname Inc